May 27, 2024
Allogeneic Stem Cell Transplantation Market

Allogeneic Stem Cell Transplantation Market Driven By Increasing Prevelance Of Cancer

The global Allogeneic Stem Cell Transplantation Market is estimated to be valued at US$ 3.9 Billion In 2022 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 – 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Allogeneic stem cell transplantation is a procedure where a patient receives healthy stem cells from a matched donor. These stem cells can be either bone marrow, peripheral blood or umbilical cord blood. The stem cells help replace the damaged or destroyed bone marrow in patients suffering from blood cancers like leukemia, lymphoma or other bone marrow diseases. Allogeneic stem cell transplantation offers benefits such as potential cure for certain blood cancers, improved recovery time post-transplant and reduced risk of relapse. The increasing prevalence of cancer worldwide along with rising preference for regenerative medicine has boosted the demand for allogeneic stem cell transplantation procedures.

Market Key Trends:

One of the key trends in the allogeneic stem cell transplantation market is the increasing focus on clinical research evaluating the efficacy of this procedure for treating other conditions apart from cancers. For instance, ongoing clinical trials are evaluating the use of allogeneic stem cells for treating diseases such as diabetes, multiple sclerosis and Alzheimer’s. Moreover, innovations in stem cell preservation techniques are anticipated to boost the Allogeneic Stem Cell Transplantation Market growth. Companies are developing novel approaches for storing stem cells at lower temperatures to increase shelf life and viability of stem cell products. Furthermore, expansion of stem cell banking facilities globally is also expected to surge market expansion over the forecast period.

Porter’s Analysis

Threat of new entrants: The threat of new entrants is moderate. Significant capital investment is required for R&D, clinical trials and regulatory approvals which make entry barriers high.

Bargaining power of buyers: The bargaining power of buyers is high. Multiple treatment options are available for patients and the demand for the therapy is inelastic.

Bargaining power of suppliers: The bargaining power of suppliers is moderate. Large manufacturers have significant influence over pricing however, new biotech companies are entering the market.

Threat of new substitutes: The threat of new substitutes is high. Continued research is being conducted to develop new stem cell therapies and gene therapies which can replace allogeneic transplantation procedures.

Competitive rivalry: High due to presence of many global and local players.

Key Takeaways

The global allogeneic stem cell transplantation market size is expected to reach US$ 3.9 Billion By 2023, exhibiting a CAGR of 7.9% over the forecast period, due to increasing prevalence of cancer and other blood-related disorders.

The US dominated the North America market in 2020 owing to higher disease incidence and availability of advanced healthcare facilities. According to the American Cancer Society, approximately 1.9 million new cancer cases were reported in the US in 2020.

Key players operating in the allogeneic stem cell transplantation market are Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., MEDIPOST Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Cellular Biomedicine Group, Inc., Biosolution Co., Ltd., StemCell Technologies Inc., Caladrius Biosciences, Inc., TiGenix N.V., ViaCord, Vericel Corporation, Regen Biopharma Inc., Gamida Cell Ltd., Histogenics Corporation, BrainStorm Cell Therapeutics Inc., Lineage Cell Therapeutics, Inc.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it